Welcome to our dedicated page for Cartesian news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian stock.
Cartesian Therapeutics, Inc. (symbol: RNAC) is a clinical-stage biopharmaceutical company dedicated to developing innovative RNA-based therapies. The company utilizes its proprietary RNA Armory® platform, which introduces mRNA molecules into cells to enhance their function while naturally degrading over time without integrating into the cell's genetic material. This technology aims to provide precise control and optimization of engineered cells for a variety of cell therapies.
Cartesian Therapeutics is currently focusing on several key projects, including Descartes-08 for treating myasthenia gravis and Descartes-15, which targets systemic lupus erythematosus. These promising therapies are part of the company's portfolio of candidates that leverage multiple modalities to address complex diseases. The company's leading candidate, Descartes-08, is in its Phase 2b trial, with topline data expected by mid-2024.
The company has formed strategic partnerships to further enhance its research and development efforts. These collaborations aim to expedite the clinical trials and bring novel treatments to market efficiently. Cartesian Therapeutics also maintains a strong financial position, ensuring sufficient resources to advance its pipeline projects.
Investors and stakeholders can stay informed about the company's latest developments through regular updates on financial performance, clinical trial progress, and strategic initiatives. Recent news highlights include the approval of proposals at the company's special meeting of stockholders held on March 27, 2024, and the ongoing positive trajectory of clinical trials.
In summary, Cartesian Therapeutics is at the forefront of biopharmaceutical innovation, utilizing cutting-edge RNA technology to develop therapies for unmet medical needs. The company's commitment to advancing its pipeline and maintaining strategic partnerships positions it as a significant player in the biopharmaceutical industry.
Cartesian Therapeutics (NASDAQ: RNAC) announced that safety and tolerability data for Descartes-08, their lead mRNA cell therapy candidate, will be presented at the 66th ASH Annual Meeting in December 2024. The presentation will focus on their autologous mRNA-engineered CAR-T therapy targeting BCMA. The poster presentation, titled 'Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Diseases,' will be delivered by CMO Miloš Miljković. The poster was also selected for inclusion in the ASH Poster Walk on Blood Immunology & Cellular Therapy.
Cartesian Therapeutics (NASDAQ: RNAC) presented data from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG) at the 2024 MGFA Scientific Session of the AANEM Annual Meeting. The trial achieved its primary endpoint with statistical significance, with 71% of Descartes-08 treated patients showing ≥5-point improvements in MG Composite score at Month 3 compared to 25% in the placebo group (p=0.018).
Descartes-08, an autologous mRNA-engineered CAR-T therapy targeting BCMA, demonstrated a favorable safety profile supporting outpatient administration without preconditioning chemotherapy. The treatment was associated with reduced anti-AChR antibody titer levels and did not lead to decreased vaccine titers or increased infection rates.
Cartesian plans to hold an End-of-Phase 2 meeting with the FDA by year-end 2024 to discuss initiating a Phase 3 clinical trial of Descartes-08 in MG.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company focusing on mRNA cell therapies for autoimmune diseases, has announced inducement awards for five new employees. On October 1, 2024, the company granted these employees options to purchase a total of 60,961 shares of common stock at an exercise price of $17.11 per share, which was the closing price on Nasdaq on the grant date.
The options were issued under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board of directors. They will vest 25% on October 1, 2025, followed by three equal annual installments, becoming fully vested on October 1, 2028. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Cartesian Therapeutics (NASDAQ: RNAC) has received FDA Rare Pediatric Disease Designation for Descartes-08, its lead mRNA cell therapy candidate for treating juvenile dermatomyositis (JDM). Descartes-08 is an autologous mRNA-engineered CAR-T therapy targeting BCMA, designed for administration without preconditioning chemotherapy. The company plans to file an IND for a Phase 2 pediatric basket study by year-end, focusing on neurology and rheumatology autoimmune indications, including JDM.
This designation recognizes Descartes-08's potential as a therapeutic option for an underserved pediatric population. If approved for JDM, Cartesian may qualify for a priority review voucher, which can expedite future marketing applications.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focusing on mRNA cell therapies for autoimmune diseases, has granted an inducement award to a new employee. The award, issued on September 3, 2024, consists of an option to purchase 3,864 shares of the company's common stock at an exercise price of $13.12 per share. This price reflects the closing price of RNAC on Nasdaq on the grant date.
The option, approved by the board of directors, falls under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan. It has a four-year vesting schedule, with 25% vesting on September 3, 2025, and the remainder vesting in three equal annual installments until fully vested by September 3, 2028. The option has a ten-year term and was granted under Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Cartesian Therapeutics (NASDAQ: RNAC) has dosed the first patient in a Phase 1 trial of Descartes-15, its next-generation autologous anti-BCMA mRNA CAR-T cell therapy. Designed for outpatient administration without preconditioning chemotherapy, Descartes-15 showed a ten-fold increase in CAR expression and target-specific killing compared to Descartes-08 in preclinical studies. The trial (NCT06304636) will evaluate safety and tolerability in multiple myeloma patients. CEO Carsten Brunn highlighted the therapy's potential for autoimmune diseases with high unmet need. Descartes-15 features enhanced CAR stability and predictable pharmacokinetics, positioning it as a potentially potent next-generation cell therapy.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focusing on mRNA cell therapy for autoimmune diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 2:30 p.m. ET in New York, NY
2. Cantor Global Healthcare Conference on September 17 at 9:45 a.m. ET in New York, NY
The company's management will participate in fireside chats at both events. Live webcasts of these discussions will be available on the Events section of Cartesian Therapeutics' website, with archived replays accessible for a time.
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2024 financial results and provided a business update. Key highlights:
1. Positive topline results from Phase 2b trial of Descartes-08 in myasthenia gravis patients.
2. First SLE patient dosed in Phase 2 trial of Descartes-08.
3. IND filing for pediatric basket study of Descartes-08 expected by year-end.
4. $130 million PIPE financing completed to support Descartes-08 development.
5. Q2 2024 financials: $88.9 million in cash, $12.7 million R&D expenses, $7.0 million G&A expenses.
6. Net income of $13.8 million, including $30 million milestone fee from Sobi.
The company plans an End-of-Phase 2 meeting with FDA by year-end and aims to initiate a Phase 3 trial in MG.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on mRNA cell therapies for autoimmune diseases, has granted inducement awards to seven new employees. The company issued options to purchase a total of 100,457 shares of common stock at an exercise price of $15.47 per share, matching the closing price on Nasdaq on August 1, 2024. These options, approved by the board of directors, were granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan. The vesting schedule is 25% on August 1, 2025, followed by three equal annual installments, with full vesting by August 1, 2028. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on mRNA cell therapies for autoimmune diseases, announced employment inducement grants.
On July 1, 2024, the company issued options to purchase 35,198 shares of common stock at $24.27 per share, the closing price on the grant date.
The options vest 25% on July 1, 2025, with the remaining shares vesting in three equal annual installments until fully vested on July 1, 2028.
These awards were issued under the 2018 Employment Inducement Incentive Award Plan and approved by the board, granted under Rule 5635(c)(4) of Nasdaq Listing Rules.
FAQ
What is the current stock price of Cartesian (RNAC)?
What is the market cap of Cartesian (RNAC)?
What does Cartesian Therapeutics, Inc. do?
What is the RNA Armory® platform?
What are Cartesian Therapeutics' key projects?
What is the status of Descartes-08?
How does Cartesian Therapeutics ensure the success of its clinical trials?
What recent achievements has Cartesian Therapeutics announced?
What makes Cartesian Therapeutics unique in the biopharmaceutical industry?
How does Cartesian Therapeutics support its financial health?
Where can investors find updates about Cartesian Therapeutics?
What is the significance of Cartesian Therapeutics' RNA therapies?
